Open AccessThe use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis
Author(s) -
Pelham Barton,
Paresh Jobanputra,
J.L. Wilson,
Stirling Bryan,
Amanda Burls
Publication year - 2004
Publication title -
health technology assessment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.426
H-Index - 126
eISSN - 2046-4924
pISSN - 1366-5278
DOI - 10.3310/hta8110
Subject(s) - medicine , rheumatoid arthritis , antibody , rheumatoid factor , intensive care medicine , tumor necrosis factor alpha , necrosis , immunology , surgery
To address the structural issues relating to mortality and quality of life (QoL) effects and to identify data on the general pattern of QoL of rheumatoid arthritis (RA) patients through a restructured and enhanced version of the Birmingham Preliminary Model (BPM).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom